FluidForm Bio™, today announced the publication of a groundbreaking paper in the journal Science Advances detailing the development of CHIPS (Collagen-based High-resolution Internally Perfusable Scaffolds), a fully-biologic, 3D-bioprinted tissue platform engineered for internal perfusion and organ-level function. The work, led by Dr. Adam Feinberg and colleagues at Carnegie Mellon University, demonstrates the ability to fabricate centimeter-scale tissue constructs combining cells and extracellular matrix with unprecedented precision and functional fidelity.

FluidForm Bio™, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,215,202 B2, titled, “Additive Manufacturing Support Material.” This newly issued patent expands the foundational intellectual property exclusively licensed to the company from Carnegie Mellon University around FRESH™ (Freeform Reversible Embedding of Suspended Hydrogels), a proprietary bioprinting platform that enables the clinical-grade manufacturing of functional human tissue.

FluidForm Bio™, today announced a major advancement in vascularized tissue engineering. A newly published study in ACS Biomaterials Science & Engineering demonstrates how FRESH™ 3D bioprinting, combined with sacrificial gelatin microparticles, significantly enhances cell viability in thick tissue constructs by improving nutrient diffusion and enabling scalable perfusion strategies.

FluidForm Bio™, announced that Mike Graffeo, CEO and co-founder, will deliver a company overview and conduct one-on-one meetings at Venture Summit West, which is being held April 2-3 in Mountain View, CA.

FluidForm Bio™, announced that Adam Feinberg, PhD, FluidForm Co-Founder and Chief Technology Officer, and Professor, Biomedical Engineering and Materials Science & Engineering, Carnegie Mellon University, will participate in a panel discussion at the 2025 SXSW Conference & Exhibits, which is being held March 7-15 in Austin, Texas.

FluidForm Bio™, announced that Mike Graffeo, CEO and co-founder, will deliver a company overview and conduct one-on-one meetings at Biotech Showcase, which is being held January 13-15, in San Francisco.

FluidForm Bio™, announced that Mike Graffeo, CEO and co-founder, will delivery a company overview and conduct one-on-one meetings at the New England Venture Summit, which is being held December 10-11 in Boston, MA.

FluidForm Bio™, announced that it has named Jonathan Paris as general counsel and head of corporate strategy, Naomi Phaneuf as chief marketing officer, and Alex Lenz as vice president of people & business operations

FluidForm Bio, a leader in developing life-like human tissue to treat disease, shares recent advancements in building human cardiac tissues using FRESH™ 3D bioprinting.

FluidForm’s CDDP is the first tool to give actionable, translationally relevant signals at the critical juncture of lead selection and lead optimization.

Amgen’s research site in Burnaby, British Columbia, Canada, is working to build human immune system models that can help predict immune reactions to medicines in development.

FluidForm, a leader in the field of recreating human tissue to radically transform drug discovery, surgical repair, and replacement, today announced an investment from Hackensack Meridian Health and its Bear’s Den innovation program.

FluidForm, a leader in the field of human tissue for research, repair, and replacement, signed an agreement with Ethicon, Inc., a member of the Johnson & Johnson Medical Devices Companies, to develop 3D Bioprinted applications using FluidForm’s patented FRESH technology.

CTO Adam Feinberg named to 3D Natives Most Influential Personalities in Additive Manufacturing

Wired writes about research at Carnegie Mellon printing a full sized heart model using FRESH

Fast Company’s recognition of companies with “world-changing” ideas today was timely and symbolic. As the world navigates a way forward, Fast Company and others demonstrate that the show must and will go on. World-changing ideas cannot wait.

NIH Director’s blog reviewed the Science paper and the promise of FRESH printing

Scientists have taken a major step closer to being able to 3D bioprint functional organs, after researchers devised a method of rebuilding components of the human heart, according to a study published in the August 2nd edition of Science.

CTO Adam Feinberg speaks at the World Economic Forum

USPTO highlights FRESH in their Science of Innovation series